Actionable news
All posts from Actionable news
Actionable news in AGN: ALLERGAN Inc,

Evidence Pfizer Could Revisit GlaxoSmithKline Or AstraZeneca Deals If Allergan Falls Through

Invest with Confidence. Are you a financial professional? Stay on top of your portfolio with Benzinga Pro's real-time newsfeed and alerts and never miss a headline again.
Don't miss the chance to try it FREE today.

Despite the proposed merger agreement with Allergan plc Ordinary Shares AGN 16.45%, analysts have been talking about other potential moves Pfizer Inc. PFE 2.15% could engage in if the deal were to fall through.

Based upon the imbalance between the proposed merger pricing of Allergan (at an implied $333.24/share), and the current trading price of Allergan ($232 Tuesday afternoon), analysts have observed a substantial risk that the deal will not come to fruition after all.

Analysts Look To Other Names In The Space

Analysts at Jefferies and Bernstein have both offered up GlaxoSmithKline...